JUN 17, 2019 07:22 AM PDT

Drug Delays Type 1 Diabetes in High Risk Individuals

WRITTEN BY: Nouran Amin

An immunotherapeutic, involving anti-CD3 monoclonal antibody (teplizumab), was seen to slow down the progression to clinical type 1 diabetes in high risk individuals. Findings from the National Institutes of Health-funded research show that clinical type 1 diabetes can be delayed by two or more years for individuals at high risk.

"The difference in outcomes was striking. This discovery is the first evidence we've seen that clinical type 1 diabetes can be delayed with early preventive treatment," said Lisa Spain, Ph.D., Project Scientist from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), sponsor of TrialNet. "The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment."

These results were published online in The New England Journal of Medicine and presented at the American Diabetes Association Scientific Sessions in San Francisco.

"Previous clinical research funded by the NIH found that teplizumab effectively slows the loss of beta cells in people with recent onset clinical type 1 diabetes, but the drug had never been tested in people who did not have clinical disease," said Kevan C. Herold, M.D., of Yale University, the study's lead author. "We wanted to see whether early intervention would have a benefit for people who are at high risk but do not yet have symptoms of type 1 diabetes."

Type 1 diabetes is a result of the immune system attacking its own insulin-producing cells. Insulin is critical for converting glucose into energy. However, with Teplizumab, it works by targeting the cells that recognize the insulin producing cells as ‘foreign’—lessening the destruction.

Learn more about Type 1 Diabetes:

"While the results are encouraging, more research needs to be done to address the trial's limitations, as well as to fully understand the mechanisms of action, long-term efficacy and safety of the treatment," said Dr. Spain.

"This trial illustrates how decades of research on the biology of type 1 diabetes can lead to promising treatments that have a real impact on people's lives. We're very excited to see the next steps in this research," said Dr. Griffin P. Rodgers, NIDDK Director. "The dedicated researchers, volunteers and families participating in this program make discoveries like this possible."

Source: National Institutes of Health

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Generic Weight Loss Drug Safe & Effective for Long-Term Use
In a study published in Obesity, an inexpensive weight-loss drug FDA-approved 60 years ago for a three month short-term use-- may now be regarded as safe a...
JUL 19, 2019
Health & Medicine
JUL 19, 2019
The Healthiest Gut Makes the Healthiest Mind
  In a study published in February in the journal, Nature researchers report more evidence that microbial diversity in the human digestive system and...
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Hypertensive Drug Could Treat An Array of Neurodegenerative Diseases
In studies carried out on mice and zebrafish, a prescribed drug for hypertension may be promising for treating a collection of neurodegenerative diseases. ...
JUL 19, 2019
Drug Discovery
JUL 19, 2019
Benralizumab not effective reducing exacerbations of COPD
According to the American Lung Association, chronic obstructive pulmonary disease (COPD) is the third leading cause of death in this country. More than oft...
JUL 19, 2019
Drug Discovery
JUL 19, 2019
'Sugar-coating' proteins to treat pancreatitis?
A powerful biomarker created by complex sugar molecules, called CA19-9, may be a target for the treatment of pancreatitis. Pancreatitis is an inflammatory ...
JUL 19, 2019
Health & Medicine
JUL 19, 2019
High Risk: Seizures and Coma Linked to Use of Synthetic Cannabinoids in Adolescents
A recent study by the American Academy of Pediatrics states that exposure to acute synthetic cannabinoid toxicity is far more dangerous to the adolesc...
Loading Comments...